Cardiovascular Business August 7, 2024
Medtronic and Abbott, two of the world’s largest healthcare technology companies, have launched a new partnership focused on improving care for patients with type 1 and type 2 diabetes.
The two companies, typically seen as rivals in the competitive diabetes care landscape, are joining forces on a new continuous glucose monitor (CGM) that will use Abbott’s own FreeStyle Libre sensors and work exclusively with Medtronic’s smart insulin delivery systems and software. The partnership covers both automated insulin delivery (AID) and multiple daily injection (MDI) systems, and the final products will be sold exclusively by Medtronic. The groups hope to improve access to CGM devices around the world, providing an essential resource for patients with both type 1 and type...
Today's Sponsors
Today's Sponsor